Mackenzie Financial Corp lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 1,153.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,930 shares of the biopharmaceutical company’s stock after acquiring an additional 52,389 shares during the quarter. Mackenzie Financial Corp’s holdings in Intra-Cellular Therapies were worth $3,250,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also modified their holdings of ITCI. US Bancorp DE increased its position in shares of Intra-Cellular Therapies by 93.8% during the second quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 240 shares during the period. Assetmark Inc. increased its position in shares of Intra-Cellular Therapies by 410.0% during the second quarter. Assetmark Inc. now owns 510 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 410 shares during the period. Prospera Financial Services Inc purchased a new stake in shares of Intra-Cellular Therapies during the first quarter worth $71,000. Exchange Traded Concepts LLC increased its position in shares of Intra-Cellular Therapies by 138.3% during the second quarter. Exchange Traded Concepts LLC now owns 1,299 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 754 shares during the period. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Intra-Cellular Therapies during the second quarter worth $207,000. Hedge funds and other institutional investors own 85.48% of the company’s stock.
Insider Buying and Selling at Intra-Cellular Therapies
In other Intra-Cellular Therapies news, CFO Lawrence J. Hineline sold 65,164 shares of the company’s stock in a transaction on Wednesday, September 21st. The shares were sold at an average price of $45.63, for a total value of $2,973,433.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.70% of the stock is currently owned by insiders.
Analysts Set New Price Targets
Intra-Cellular Therapies Price Performance
NASDAQ ITCI opened at $51.94 on Monday. Intra-Cellular Therapies, Inc. has a 1 year low of $34.43 and a 1 year high of $66.00. The company has a market capitalization of $4.92 billion, a PE ratio of -15.64 and a beta of 1.15. The company has a fifty day moving average of $47.92 and a two-hundred day moving average of $52.30.
Intra-Cellular Therapies Company Profile
Intra-Cellular Therapies, Inc, a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults.
- Get a free copy of the StockNews.com research report on Intra-Cellular Therapies (ITCI)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.